Mark Vignola Net Worth

Mark Vignola biography

Mark J. Vignola Ph.D. serves as Chief Financial Officer of the Company. Prior to joining the company, from June 2015 to April 2019, he was Executive Director and Head of Corporate Development and Investor Relations at Intercept Pharmaceuticals, a biopharmaceutical company. From July 2011 to May 2015, he was a member of the biotechnology equity research team at Needham and Co. Dr. Vignola received his B.S. in biology from Boston College and a Ph.D. in Molecular Genetics and Microbiology from Duke University.

What is the salary of Mark Vignola?

As the Chief Financial Officer of Applied Therapeutics, the total compensation of Mark Vignola at Applied Therapeutics is $2,077,030. There are 2 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.

What's Mark Vignola's mailing address?

Mark's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10173.

Insiders trading at Applied Therapeutics

Over the last 5 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus, eShoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.

What does Applied Therapeutics do?

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics executives and stock owners

Applied Therapeutics executives and other stock owners filed with the SEC include:

• shoshana Shendelman,
  Chairman of the Board, President, Chief Executive Officer, Founder
• Riccardo Perfetti,
  Chief Medical Officer
• Mark Vignola,
  Chief Financial Officer
• Dr. Shoshana Shendelman Ph.D.,
  Chair of the Board of Directors, Founder, Pres, CEO & Sec.
• Dr. Riccardo Perfetti,
  Chief Medical Officer
• Leslie Funtleyder,
  Independent Director
• Dr. Charles Silberstein M.D., CFA,
  CFO & Head of Bus. Devel.
• Teena Lerner,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Stacy Kanter,
  Independent Director
• Jay Skyler,
  Independent Director
• Maeve Conneighton,
  IR Contact Officer
• Adam Hansard,
  Chief Commercial Officer
• Chids Mahadevan,
  VP of Fin. & Chief Accounting Officer
• Real Estate Equities, Inc.A...,
  
• Constantine Chinoporos,
  See Remarks
• Charles Silberstein,
  Chief Financial Officer
• Adam Hansard,
  Chief Commercial Officer
• Corwin Dale Hooks,
  Chief Commercial Officer
• Steven A. Ortega,
  Principal Accounting Officer
• Chids Mahadevan,
  See Remarks